Iranian Journal of Medical Sciences

Iranian Journal of Medical Sciences

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Journal Team

Publication Ethics

Indexing and Abstracting

Related Links

Peer Review Process

Journal Metrics

Analysis of CYP2D6 Gene Variant Frequencies in Iranian Population

Document Type : Original Article(s)

Authors

1 Medical Genomic Research Center, Tehran Medical Sciences Islamic Azad University, Tehran, Iran

2 Department of Toxicology and Pharmacology, Faculty of Pharmacy and Pharmaceutical Sciences, Islamic Azad University, Tehran Medical Sciences (IAUTMU), Tehran, Iran

3 Department of Medical Genetics, School of Medicine, Zahedan University of Medical Sciences (ZAUMS), Zahedan, Iran

4 Cellular and Molecular Research Center, Research Institute of Cellular and Molecular Sciences in Infectious Diseases, Zahedan University of Medical Sciences, Iran

5 Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: The cytochrome P450 (P450s or CYPs) enzyme family, particularly CYP2D6, significantly influences drug metabolism, handling approximately 20-25% of prescribed medications. Understanding genetic polymorphisms is crucial for personalized medicine and optimizing drug therapy in specific geographic and racial contexts. Given the complex nature of studying CYP2D6 genotypes, this study aimed to assess the prevalence of rare CYP2D6 star alleles, including rs267608319 (CYP2D6*31), rs1931013246 (CYP2D6*55), rs569439709 (CYP2D6*113), and rs747089665 (CYP2D6*135), within the Iranian population. 
Methods: Blood samples were obtained from 389 individuals across several ethnic groups in Tehran, Iran, from May to December 2022. PCR was used to amplify the region containing the desired variant. Genotyping was performed using the Sanger sequencing method.
Results: Our analysis revealed a high frequency of normal alleles for all four studied variants, indicating the absence of the risk allele in the Iranian population. These findings suggest that the studied alleles have no apparent effect on various ethnic groups in Iran.
Conclusion: The Iranian population has a typical genetic makeup for CYP2D6 variations, impacting medication prescribing. Understanding genetic differences is crucial for personalized drug therapies. Further research into Iranian genetic variations is essential for advancing personalized medicine.

Keywords

References
  1. van Schaik RHN, Muller DJ, Serretti A, Ingelman-Sundberg M. Pharmacogenetics in Psychiatry: An Update on Clinical Usability. Front Pharmacol. 2020;11:575540. doi: 10.3389/fphar.2020.575540. PubMed PMID: 33041820; PubMed Central PMCID: PMCPMC7518035.
  2. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel). 2020;11. doi: 10.3390/genes11111295. PubMed PMID: 33143137; PubMed Central PMCID: PMCPMC7692531.
  3. Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17:165-84. doi: 10.1007/s40291-013-0028-5. PubMed PMID: 23588782; PubMed Central PMCID: PMCPMC3663206.
  4. Nofziger C, Turner AJ, Sangkuhl K, Whirl-Carrillo M, Agundez JAG, Black JL, et al. PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther. 2020;107:154-70. doi: 10.1002/cpt.1643. PubMed PMID: 31544239; PubMed Central PMCID: PMCPMC6925641.
  5. Twesigomwe D, Drogemoller BI, Wright GEB, Adebamowo C, Agongo G, Boua PR, et al. Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations. Clin Pharmacol Ther. 2023;113:643-59. doi: 10.1002/cpt.2749. PubMed PMID: 36111505; PubMed Central PMCID: PMCPMC9957841.
  6. Gaedigk A, Casey ST, Whirl-Carrillo M, Miller NA, Klein TE. Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation. Clin Pharmacol Ther. 2021;110:542-5. doi: 10.1002/cpt.2321. PubMed PMID: 34091888; PubMed Central PMCID: PMCPMC8725060.
  7. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet. 1989;45:889-904. PubMed PMID: 2574001; PubMed Central PMCID: PMCPMC1683468.
  8. Bell GC, Caudle KE, Whirl-Carrillo M, Gordon RJ, Hikino K, Prows CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102:213-8. doi: 10.1002/cpt.598. PubMed PMID: 28002639; PubMed Central PMCID: PMCPMC5479760.
  9. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110:888-96. doi: 10.1002/cpt.2149. PubMed PMID: 33387367; PubMed Central PMCID: PMCPMC8249478.
  10. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018;103:770-7. doi: 10.1002/cpt.1007. PubMed PMID: 29385237; PubMed Central PMCID: PMCPMC5931215.
  11. Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Muller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102:37-44. doi: 10.1002/cpt.597. PubMed PMID: 27997040; PubMed Central PMCID: PMCPMC5478479.
  12. Hicks JK, Bishop JR, Sangkuhl K, Muller DJ, Ji Y, Leckband SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015;98:127-34. doi: 10.1002/cpt.147. PubMed PMID: 25974703; PubMed Central PMCID: PMCPMC4512908.
  13. Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci. 2020;13:116-24. doi: 10.1111/cts.12692. PubMed PMID: 31647186; PubMed Central PMCID: PMCPMC6951851.
  14. Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Leeder JS. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19:69-76. doi: 10.1038/gim.2016.80. PubMed PMID: 27388693; PubMed Central PMCID: PMCPMC5292679.
  15. Khalaj Z, Baratieh Z, Nikpour P, Khanahmad H, Mokarian F, Salehi R, et al. Distribution of CYP2D6 polymorphism in the Middle Eastern region. J Res Med Sci. 2019;24:61. doi: 10.4103/jrms.JRMS_1076_18. PubMed PMID: 31523247; PubMed Central PMCID: PMCPMC6670283.
  16. Numanagic I, Malikic S, Ford M, Qin X, Toji L, Radovich M, et al. Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes. Nat Commun. 2018;9:828. doi: 10.1038/s41467-018-03273-1. PubMed PMID: 29483503; PubMed Central PMCID: PMCPMC5826927.
  17. Twesigomwe D, Drogemoller BI, Wright GEB, Siddiqui A, da Rocha J, Lombard Z, et al. StellarPGx: A Nextflow Pipeline for Calling Star Alleles in Cytochrome P450 Genes. Clin Pharmacol Ther. 2021;110:741-9. doi: 10.1002/cpt.2173. PubMed PMID: 33492672.
  18. Lee SB, Shin JY, Kwon NJ, Kim C, Seo JS. ClinPharmSeq: A targeted sequencing panel for clinical pharmacogenetics implementation. PLoS One. 2022;17:e0272129. doi: 10.1371/journal.pone.0272129. PubMed PMID: 35901010; PubMed Central PMCID: PMCPMC9333201.
  19. PharmGKB [Internet]. Gene-specific Information Tables for CYP2D6. c2001-2024. Available from: https://www.pharmgkb.org/page/cyp2d6RefMaterials
  20. Blancas I, Rodriguez Gonzalez CJ, Munoz-Serrano AJ, Delgado MT, Legeren M, Gonzalez Astorga B, et al. Influence of CYP2D6 polymorphism in the outcome of breast cancer patients undergoing tamoxifen adjuvant treatment. American Society of Clinical Oncology. 2018;36:e12521. doi: 10.1200/JCO.2018.36.15_suppl.e12521.
  21. Adithan C, Gerard N, Naveen AT, Koumaravelou K, Shashindran CH, Krishnamoorthy R. Genotype and allele frequency of CYP2D6 in Tamilian population. Eur J Clin Pharmacol. 2003;59:517-20. doi: 10.1007/s00228-003-0657-4. PubMed PMID: 12942225.
  22. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229-43. doi: 10.1517/14622416.3.2.229. PubMed PMID: 11972444.
  23. Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schroder T, et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther. 1999;66:185-92. doi: 10.1053/cp.1999.v66.100072001. PubMed PMID: 10460072.
  24. Shiran MR, Sarzare F, Merat F, Salehifar E, Moghadamnia AA, Hashemi Soteh SM. Metabolic capacity of CYP2D6 within an Iranian population (Mazandaran Province). Caspian J Intern Med. 2011;2:213-7. PubMed PMID: 24024018; PubMed Central PMCID: PMCPMC3766937.
  25. Bagheri A, Kamalidehghan B, Haghshenas M, Azadfar P, Akbari L, Sangtarash MH, et al. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities. Drug Des Devel Ther. 2015;9:2627-34. doi: 10.2147/DDDT.S79709. PubMed PMID: 25999696; PubMed Central PMCID: PMCPMC4435087.
  26. Kouhi H, Hamzeiy H, Barar J, Asadi M, Omidi Y. Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test Mol Biomarkers. 2009;13:665-70. doi: 10.1089/gtmb.2009.0009. PubMed PMID: 19715474.
  27. Reference SNP (rs) Report [Internet]. National Library of medicine, National Center for Biotechnology Information (NCBI); . (n.d.). NCBI. [Cited 4 April 2024]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs267608319
  28. Montane Jaime LK, Lalla A, Steimer W, Gaedigk A. Characterization of the CYP2D6 gene locus and metabolic activity in Indo- and Afro-Trinidadians: discovery of novel allelic variants. Pharmacogenomics. 2013;14:261-76. doi: 10.2217/pgs.12.207. PubMed PMID: 23394389.
  29. Yamazaki H, Kiyotani K, Tsubuko S, Matsunaga M, Fujieda M, Saito T, et al. Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet. 2003;18:269-71. doi: 10.2133/dmpk.18.269. PubMed PMID: 15618746.
  30. Kiyotani K, Shimizu M, Kumai T, Kamataki T, Kobayashi S, Yamazaki H. Limited effects of frequent CYP2D6*36-*10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. Eur J Clin Pharmacol. 2010;66:1065-8. doi: 10.1007/s00228-010-0876-4. PubMed PMID: 20700584.
  31. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J. 2009;9:34-41. doi: 10.1038/tpj.2008.7. PubMed PMID: 18591960.
  32. Gaedigk A, Isidoro-Garcia M, Pearce RE, Sanchez S, Garcia-Solaesa V, Lorenzo-Romo C, et al. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur J Clin Pharmacol. 2010;66:859-64. doi: 10.1007/s00228-010-0831-4. PubMed PMID: 20473659.
  33. von Ahsen N, Tzvetkov M, Karunajeewa HA, Gomorrai S, Ura A, Brockmoller J, et al. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int J Mol Epidemiol Genet. 2010;1:310-9. PubMed PMID: 21532842; PubMed Central PMCID: PMCPMC3076784.
  34. Reference SNP(rs) Report [Internet]. National Center for Biotechnology Information. [cited 21 Sptember 2022]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs1931013246
  35. Ebisawa A, Hiratsuka M, Sakuyama K, Konno Y, Sasaki T, Mizugaki M. Two novel single nucleotide polymorphisms (SNPs) of the CYP2D6 gene in Japanese individuals. Drug Metab Pharmacokinet. 2005;20:294-9. doi: 10.2133/dmpk.20.294. PubMed PMID: 16141609.
  36. Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, et al. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 2009;9:380-94. doi: 10.1038/tpj.2009.31. PubMed PMID: 19636337.
  37. Jin TB, Ma LF, Zhang JY, Yuan DY, Sun Q, Zong TY, et al. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population. Gene. 2013;527:360-5. doi: 10.1016/j.gene.2013.03.110. PubMed PMID: 23644254.
  38. Qian JC, Xu XM, Hu GX, Dai DP, Xu RA, Hu LM, et al. Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics. 2013;14:1731-43. doi: 10.2217/pgs.13.160. PubMed PMID: 24192122.
  39. Reference SNP (rs) Report [Internet]. National Library of medicine, National Center for Biotechnology Information (NCBI); . (n.d.). NCBI. [cited 21 Sptember 2022]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs569439709
  40. Reference SNP (rs) Report [Internet]. National Center for Biotechnology Information. [cited 21 Sptember 2022]. Available from: https://www.ncbi.nlm.nih.gov/snp/rs747089665
  41. Ramli FF. Pharmacogenomics biomarkers for personalized methadone maintenance treatment: The mechanism and its potential use. Bosn J Basic Med Sci. 2021;21:145-54. doi: 10.17305/bjbms.2020.4897. PubMed PMID: 32841585; PubMed Central PMCID: PMCPMC7982063.
Iranian Journal of Medical Sciences
Volume 50, Issue 5
May 2025
Pages 351-358
Files
History
  • Received: 18 May 2024
  • Revised: 13 August 2024
  • Accepted: 06 September 2024
Share
How to cite
Statistics